- Featured Product
- KD/KO Validated
TGFBI / BIGH3 Polyclonal antibody
TGFBI / BIGH3 Polyclonal Antibody for FC, IF, IHC, IP, WB, ELISA
Cat no : 10188-1-AP
Validation Data Gallery
|Positive WB detected in
|mouse eye tissue, mouse liver tissue, human kidney tissue, Y79 cells, HeLa cells
|Positive IP detected in
|Positive IHC detected in
|human kidney tissue, human liver cancer tissue, mouse eye tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in
|TGF beta 1 treated A549 cells
|Positive FC detected in
|Western Blot (WB)
|WB : 1:1000-1:4000
|IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
|IHC : 1:50-1:500
|IF : 1:200-1:800
|Flow Cytometry (FC)
|FC : 0.40 ug per 10^6 cells in a 100 µl suspension
|It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
|Sample-dependent, check data in validation data gallery
10188-1-AP targets TGFBI / BIGH3 in WB, Neutralization, IP, IHC, IF, FC, ELISA applications and shows reactivity with human, mouse samples.
|human, mouse, rat
|Host / Isotype
|Rabbit / IgG
|TGFBI / BIGH3 fusion protein Ag0241
|transforming growth factor, beta-induced, 68kDa
|Calculated molecular weight
|683 aa, 75 kDa
|Observed molecular weight
|GenBank accession number
|Gene ID (NCBI)
|Antigen affinity purification
|PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
|Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.
TGFBI, also named as BIGH3, Kerato-epithelin and RGD-CAP, binds to type I, II, and IV collagens. TGFBI is an adhesion protein which may play an important role in cell-collagen interactions. In cartilage, it may be involved in endochondral bone formation. TGFBI is an extracellular matrix adaptor protein, it has been reported to be differentially expressed in transformed tissues. TGFBI is a predictive factor of the response to chemotherapy, and suggest the use of TGFBI-derived peptides as possible therapeutic adjuvants for the enhancement of responses to chemotherapy.(PMID:20509890) Defects in TGFBI are the cause of epithelial basement membrane corneal dystrophy (EBMD). Defects in TGFBI are the cause of corneal dystrophy Groenouw type 1 (CDGG1). Defects in TGFBI are the cause of corneal dystrophy lattice type 1 (CDL1). Defects in TGFBI are a cause of corneal dystrophy Thiel-Behnke type (CDTB). Defects in TGFBI are the cause of Reis-Buecklers corneal dystrophy (CDRB). Defects in TGFBI are the cause of lattice corneal dystrophy type 3A (CDL3A). Defects in TGFBI are the cause of Avellino corneal dystrophy (ACD).
|Product Specific Protocols
|WB protocol for TGFBI / BIGH3 antibody 10188-1-AP
|IHC protocol for TGFBI / BIGH3 antibody 10188-1-AP
|IF protocol for TGFBI / BIGH3 antibody 10188-1-AP
|IP protocol for TGFBI / BIGH3 antibody 10188-1-AP
|FC protocol for TGFBI / BIGH3 antibody 10188-1-AP
|Click here to view our Standard Protocols
Nat Cell Biol
Supermeres are functional extracellular nanoparticles replete with disease biomarkers and therapeutic targets.
Comprehensive isolation of extracellular vesicles and nanoparticles
Acetylated K676 TGFBIp as a severity diagnostic blood biomarker for SARS-CoV-2 pneumonia.
Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation.
Dual peptide-dendrimer conjugate inhibits acetylation of transforming growth factor β-induced protein and improves survival in sepsis.
TGFBI secreted by tumor-associated macrophages promotes glioblastoma stem cell-driven tumor growth via integrin αvβ5-Src-Stat3 signaling.
The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.
Carmelo (Verified Customer) (04-25-2022)
I tested the abs 1:1000 ON at 4C on 40ug spinal cord protein lysates. unfortunately I was not able to distinguish a proper band at the expected size. I will run further optimisation in the incoming weeks.